Sole Source Total Parenteral Nutrition (TPN) solutions, including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid same-day delivery, seven days a week

The Defense Health Agency Hcd West, under the Department of Defense, intends to award a five-year firm fixed price Blanket Purchase Agreement to Central Admixture Pharmacy Services, Inc. for the exclusive provision of specialized compounded intravenous solutions including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid, with guaranteed same-day delivery seven days a week to Madigan Army Medical Center at Joint Base Lewis-McChord in Tacoma, Washington. The requirement, identified by solicitation number HT941026N0069 and NAICS code 325412 (Pharmaceutical Preparation Manufacturing), is being pursued as a sole source procurement due to the exacting clinical specifications of the products, which preclude the use of substitutes. The contract period is projected to run from October 1, 2026, through September 30, 2031, encompassing an initial twelve-month base period and four one-year option periods. Delivery quantities are specified monthly for various volumes of TrophAmine/Plenamine solutions and for 100 mL units of Nutrilipid and SMOF Lipid in three-in-one TPN formulations, though unit pricing and total contract value are not disclosed. The agency has not applied any small business set-asides, and the business size standard for the NAICS code is 1,300 employees. A Notice of Intent to Sole Source has been issued, which is not a solicitation for competitive bids but provides an opportunity for other entities to challenge the intent by submitting a two-page capability statement containing management, technical, and cost information in Microsoft Word or Adobe PDF format, no smaller than 10-point font, by June 30, 2026, at 10:00 a.m. Pacific Time. All submissions must be sent electronically to the designated contracting officer and contract specialist, and telephone inquiries will not be accepted. The place of performance is clearly defined as Madigan Army Medical Center, and the products must meet strict clinical standards with no substitutions permitted. The point of contact for questions and submissions is Cha-On P. Gordon, with secondary contact Mariangela Monsalve, and all communications must adhere to the stated formatting and submission protocols.